Overview

Palbociclib With Everolimus + Exemestane In BC

Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor positive (HR+) and HER2-negative. The names of the study interventions involved in this study are: - Palbociclib - Everolimus - Exemestane
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Pfizer
Treatments:
Everolimus
Exemestane
Palbociclib
Sirolimus